price being completely controlled held down.anyways..interesting excerpt from the latest q4/Full year comentary by D.Pidduck that's particularlily interesting..
'we are now running both companies for almost 10% less than the cost of running MediPharm stand-alone in 2022. 2023 saw extensive restructuring that exceeded our VIVO synergy targets. Some of these synergies occurred later in the year and are not yet fully reflected in our annual or Q4 results.
--------
Looks like we're going up, eventually, lots of institutional hoarding as always/accumulation.